Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
RESEARCH TOOLSreports
Holding PHAT?
Track your performance easily
PHAT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.07 - $19.71
Previous Close$7.89
Volume1.02M
Average Volume (3M)1.29M
Market Cap
$539.50M
Enterprise Value$381.23M
Total Cash (Recent Filing)$334.68M
Total Debt (Recent Filing)$176.41M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Mar 04, 2025EPS Estimate
-$1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.69
Shares Outstanding68,377,379
10 Day Avg. Volume963,367
30 Day Avg. Volume1,292,160
Standard Deviation0.21
R-Squared0.02
Alpha-0.00166
Financial Highlights & Ratios
Price to Book (P/B)-2.88
Price to Sales (P/S)20.54
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.51
Enterprise Value/Gross Profit740.25
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$28.00Price Target Upside243.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Phathom Pharmaceuticals News
PremiumCompany Announcements
Phathom Pharmaceuticals Reports Significant Revenue Growth
Bulls Say, Bears Say
Bulls Say
Commercial CoverageCommercial coverage for Voquezna had increased to about 77%, indicating a significant improvement in access and availability.
Prescription GrowthVoquezna prescriptions grew sequentially by over 265%, reaching more than 35,000 filled prescriptions compared to approximately 9,500 previously.
Product LaunchVoquezna reflects the first novel innovation in GERD in over 30 years, challenging standard-of-care proton pump inhibitor limitations with its novel rapid, potent, and durable profile.
Bears Say
Commercial TrendsNormalization of commercial trends and stocking dynamics is needed before gaining confidence in the stock's potential.
Growth EvidenceAdditional evidence of a growth inflection in TRx is awaited, which could delay positive sentiment towards the stock.
Investor FocusInvestor attention is expected to focus primarily on improving patient access, which may impact stock perception.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $6.07 and its highest was $19.71 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Currently, no data Available
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 73 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$1.32 earnings per share for the quarter, beating the consensus estimate of -$1.469 by $0.149.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -$1.21.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 68,377,380 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$1.32 in its last earnings report, beating expectations of -$1.469. Following the earnings report the stock price went up 2.778%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Among the largest hedge funds holding Phathom Pharmaceuticals’s share is Woodline Partners LP. It holds Phathom Pharmaceuticals’s shares valued at 47M.
---
Phathom Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.00 (243.98% Upside)
$28.00 (243.98% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $180.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
63.32%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
---
PHAT Earnings Call
Q3 2024
0:00 / 0:00
---
PHAT Stock 12 Month Forecast
Average Price Target
$28.00
▲(243.98% Upside)
Technical Analysis
Best Analysts Covering PHAT
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+11.03%
assigned a buy rating 9 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +11.03% per trade.
---